Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06755775

PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Diffuse Large B-cell Lymphoma Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Lipodystrophy Lipodystrophy, Congenital Generalized Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Metabolic Diseases Metabolism, Inborn Errors Neoplasms Neoplasms by Histologic Type Nutritional and Metabolic Diseases Skin Diseases Skin Diseases, Metabolic Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School

Shanghai, China

Location status: Recruiting

Location contact

Biao Li

CONTACT

[email protected]

13661777388

About this study

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy (CAR-T, Glofitamab or iR2 ).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologic diagnosis of DLBCL
  • Patient's general condition is good and survival is expected to be greater than six months
  • Signed and dated informed consent form

Exclusion criteria

  • Combined with other malignant tumors
  • Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study
  • Pregnant women and women at risk of pregnancy, breastfeeding women
  • poor compliant

Treatment and study plan

Primary outcomes

  1. The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma

    Time frame: Baseline and 2 weeks after treatment

    The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma

  2. Standardized uptake value (SUV)

    Time frame: Baseline and 2 weeks after treatment

    SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions

Secondary outcomes

  1. Progress free suivival

    Time frame: 3 years

    Progress free suivival

  2. Overall survival

    Time frame: 3 years

    Overall survival

Study contacts

Contact information is provided by the study sponsor or research team.

Xinyi Zhu

CONTACT

[email protected]

19121913585

Sponsors and collaborators

Lead sponsor

Ruijin Hospital

Other

Registry information

Important dates

Study start
2024
Primary completion
2029
Study completion
2029
First posted
Jan 1, 2025
Registry last updated
Jan 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.